Patent US6329386B1 successfully refreshed from Google Patents.
US6329386B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tetrazole-containing rapamycin analogs with shortened half-lives
Assignee: Abbott Laboratories
•
Filing: 1999-11-02
•
Granted: 2001-12-11
•
Expires: 2019-11-02
Abstract
Abstract A compound having the formulaor a pharmaceutically acceptable salt or prodrug thereof, is an immunomodulatory agent and is useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal.
Inventors
- 👤 Karl W. Mollison
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 09:42
CPC Classifications
C; C07; C07D; C07D498/00; C07D498/12; C07D498/18
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
36 words
A method for inhibiting restenosis in a mammal in need of said treatment, comprising administering to the mammal a therapeutically effective amount of a compound having the formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 2
Independent Claim
36 words
A method for inhibiting restenosis in a mammal in need of said treatment, comprising administering to the mammal a therapeutically effective amount of a compound having the formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 3
Independent Claim
45 words
A method for inhibiting restenosis in a mammal in need of said treatment, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 4
Independent Claim
45 words
A method for inhibiting restenosis in a mammal in need of said treatment, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 5
Dependent Claim
23 words
The method for inhibiting restenosis in a mammal in accordance with claim 2 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
23 words
The method for inhibiting restenosis in a mammal in accordance with claim 2 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
Claim 7
Dependent Claim
22 words
The method for inhibiting restenosis in a mammal in accordance with claim 2 wherein said pharmaceutical composition further comprises a biodegradable polymer.
Claim 8
Independent Claim
45 words
A method for preventing restenosis in a mammal in need of said, prevention, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 9
Independent Claim
45 words
A method for preventing restenosis in a mammal in need of said, prevention, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 10
Dependent Claim
23 words
The method for preventing restenosis in a mammal in accordance with claim 6 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
23 words
The method for preventing restenosis in a mammal in accordance with claim 6 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
Claim 12
Dependent Claim
22 words
The method for preventing restenosis in a mammal in accordance with claim 6 wherein said pharmaceutical composition further comprises a biodegradable polymer.
Claim 13
Independent Claim
45 words
A method for treating restenosis in a mammal in need of said treatment, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 14
Independent Claim
45 words
A method for treating restenosis in a mammal in need of said treatment, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 15
Dependent Claim
23 words
The method for treating restenosis in a mammal in accordance with claim 10 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
Claim 16
Dependent Claim
23 words
The method for treating restenosis in a mammal in accordance with claim 10 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
Claim 17
Dependent Claim
22 words
The method for treating restenosis in a mammal in accordance with claim 10 wherein said pharmaceutical composition further comprises a biodegradable polymer.
Claim 18
Independent Claim
65 words
A method for treating a hyperproliferative disease in a mammal in need of said treatment, wherein said hyperproliferative disease is selected from the group consisting of vascular hyperproliferative diseases and skin hyperproliferative diseases, said method comprising administering to the mainnnal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula; or a pharmaceutically acceptable salt or prodrug thereof.
Claim 19
Independent Claim
65 words
A method for treating a hyperproliferative disease in a mammal in need of said treatment, wherein said hyperproliferative disease is selected from the group consisting of vascular hyperproliferative diseases and skin hyperproliferative diseases, said method comprising administering to the mainnnal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula; or a pharmaceutically acceptable salt or prodrug thereof.
Claim 20
Dependent Claim
25 words
The method for treating a hyperproliferative disease in a mammal in accordance with claim 14 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
25 words
The method for treating a hyperproliferative disease in a mammal in accordance with claim 14 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
Claim 22
Dependent Claim
24 words
The method for treating a hyperproliferative disease in a mammal in accordance with claim 14 wherein said pharmaceutical composition further comprises a biodegradable polymer.
Claim 23
Independent Claim
65 words
A method for preventing a hyperproliferative disease in a mamnual in need of said prevention, wherein said hyperproliferative disease is selected from the group consisting of vascular hyperproliferative diseases and skin hyperproliferative diseases, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 24
Independent Claim
65 words
A method for preventing a hyperproliferative disease in a mamnual in need of said prevention, wherein said hyperproliferative disease is selected from the group consisting of vascular hyperproliferative diseases and skin hyperproliferative diseases, said method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising a compound of a formula: or a pharmaceutically acceptable salt or prodrug thereof.
Claim 25
Dependent Claim
25 words
A method for preventing a hyperproliferative disease in a mammal in accordance with claim 18 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
Claim 26
Dependent Claim
25 words
A method for preventing a hyperproliferative disease in a mammal in accordance with claim 18 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
Claim 27
Dependent Claim
23 words
The method preventing a hyperproliferative disease in a mammal in accordance with claim 18 wherein said pharmaceutical composition further comprises a biodegradable polymer.
References Cited (Backward Citations)
US3929992A
Cited
US3993749A
Cited
US4885171A
Cited
US4316885A
Cited
US4401653A
Cited
EP0184162A2
Cited
US4650803A
Cited
EP0467606A1
Cited
US5023262A
Cited
WO1992005179A1
Cited
US5120842A
Cited
US5120842B1
Cited
US5120725A
Cited
US5120727A
Cited
US5457111A
Cited
US5177203A
Cited
WO1995014023A1
Cited
US5527907A
Cited
WO1998009972A1
Cited
WO1998009970A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-12-10 | 2005-06-11 | 2005-12-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-12-10 | 2009-06-11 | 2009-12-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-12-10 | 2013-06-11 | 2013-12-11 | $7700.00 | Window Closed / Lapsed |